Ionis Pharmaceuticals Inc. diskutieren
Ionis Pharmaceuticals Inc.
WKN: A2ACMZ / Symbol: IONS / Name: Ionis Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
68,54 €
-2,15 %
Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $95.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $80.00 price target on the stock, up previously from $49.00.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Needham & Company LLC from $70.00 to $78.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) was given a new $90.00 price target on by analysts at Morgan Stanley. They now have an "overweight" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $89.00 price target on the stock, up previously from $85.00.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Royal Bank Of Canada from $80.00 to $82.00. They now have an "outperform" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at TD Cowen from $59.00 to $99.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Piper Sandler from $70.00 to $77.00. They now have an "overweight" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at HC Wainwright from $100.00 to $110.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Bank of America Corporation from $86.00 to $97.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Leerink Partners from $85.00 to $100.00. They now have an "outperform" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $95.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its "buy" rating reaffirmed by Needham & Company LLC.
Ratings data for IONS provided by MarketBeat
Neueste Beiträge
Barrington_Research in Merit Medical Systems diskutieren